Devices

New technologies have the potential to revolutionize diabetes care. But what are the advantages and disadvantages of insulin pumps, vs. daily injections? How widely will they be adopted, by patients with type 2 diabetes as well as type 1? What factors will make a difference for adoption – convenience, accuracy, costs? In November, we asked you to help us examine the future of insulin delivery and find the answers to these questions. Now we’re sharing all the results with you, so that you can see for yourself how your fellow members of the diabetes community plan on using CGMs, now and in the future.

In this week's Homerun Slides, understanding the sensor procedure for the Eversense CGM.

In this week's Homerun Slides, explaining how the Eversense CGM System works.

In this week's Homerun Slides, we begin a review of the new Eversense CGM system.

The Omnipod Dash™ device approved for commercialization and release in the U.S. by mid-2018.

Guest Post by David Kliff, Editor, Diabetic Investor

With each passing day, it’s becoming more apparent that CGM will replace BGM as the standard for glucose measurement. CGM systems are becoming more patient-friendly, i.e. no calibrations, simple insertion, and cheaper too. The data provided by CGM is transformative, leading to improved outcomes. It is no longer a question of if this will happen but when this will happen.

Overview from a presentation at the 2018 American Diabetes Associations 78th Scientific Sessions.

The “artificial pancreas” provides glucose control for non-critically ill patients

Multi-center study compares closed-loop device to standard open-loop system in a home setting.

Hybrid closed-loop (HCL) system combines technology of CGM and insulin pumps, and a personalized, model-predictive control algorithm to deliver insulin day and night.